Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590945404> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2590945404 endingPage "48" @default.
- W2590945404 startingPage "40" @default.
- W2590945404 abstract "Superdisintegrants play important role in disintegration of orally disintegrating tablets (ODTs). Action of three different superdisintegrants, viz. croscarmellose sodium, sodium starch glycolate and Indion 414, were studied individually or in their binary combinations for their fast disintegrant action in ODTs of salbutamol sulphate prepared by direct compression.ODTs were prepared in three different superdisintegrant combinations A, B and C. In each combination, five formulations were prepared with superdisintegrants in ratios 10:90, 25:75, 50:50, 75:25, and 90:10. Three ODT formulations were prepared with single superdisintegrant and two ODT batches were prepared from marketed ODT excipient blends, viz. Prosolv-ODT and F-Melt. Prepared ODT formulations were evaluated and compared for weight variation, hardness, friability, wetting time, disintegration and drug release.All ODTs disintegrated quickly in 32 s or less. ODT formulation F3, containing croscarmellose sodium and sodium starch glycolate, disintegrated very quickly in 19.28±3.11 s. Results of F3 were compared with the batches (F19 and F20) containing marketed coprocessed excipients and found in good agreement for various evaluation parameters. Formulation F20 was hygroscopic, while F3 did not suffer this disadvantage.Thus, we may conclude that superdisintegrants in combinations may offer additive and/or synergistic disintegration possible due to their different mechanism." @default.
- W2590945404 created "2017-03-03" @default.
- W2590945404 creator A5025644172 @default.
- W2590945404 creator A5038717001 @default.
- W2590945404 date "2017-04-01" @default.
- W2590945404 modified "2023-09-29" @default.
- W2590945404 title "A Comparative Study of Different Proportions of Superdisintegrants: Formulation and Evaluation of Orally Disintegrating Tablets of Salbutamol Sulphate" @default.
- W2590945404 cites W1963646427 @default.
- W2590945404 cites W1983521939 @default.
- W2590945404 cites W2000095304 @default.
- W2590945404 cites W2000117229 @default.
- W2590945404 cites W2033085024 @default.
- W2590945404 cites W2098791557 @default.
- W2590945404 cites W2127060499 @default.
- W2590945404 cites W2128954784 @default.
- W2590945404 cites W2129555053 @default.
- W2590945404 doi "https://doi.org/10.4274/tjps.74946" @default.
- W2590945404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7227995" @default.
- W2590945404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32454593" @default.
- W2590945404 hasPublicationYear "2017" @default.
- W2590945404 type Work @default.
- W2590945404 sameAs 2590945404 @default.
- W2590945404 citedByCount "13" @default.
- W2590945404 countsByYear W25909454042019 @default.
- W2590945404 countsByYear W25909454042020 @default.
- W2590945404 countsByYear W25909454042021 @default.
- W2590945404 countsByYear W25909454042022 @default.
- W2590945404 countsByYear W25909454042023 @default.
- W2590945404 crossrefType "journal-article" @default.
- W2590945404 hasAuthorship W2590945404A5025644172 @default.
- W2590945404 hasAuthorship W2590945404A5038717001 @default.
- W2590945404 hasBestOaLocation W25909454041 @default.
- W2590945404 hasConcept C181389837 @default.
- W2590945404 hasConcept C185592680 @default.
- W2590945404 hasConcept C191168616 @default.
- W2590945404 hasConcept C201253974 @default.
- W2590945404 hasConcept C2777091354 @default.
- W2590945404 hasConcept C2777239854 @default.
- W2590945404 hasConcept C2778572730 @default.
- W2590945404 hasConcept C33923547 @default.
- W2590945404 hasConcept C43617362 @default.
- W2590945404 hasConcept C71924100 @default.
- W2590945404 hasConcept C77281830 @default.
- W2590945404 hasConcept C98274493 @default.
- W2590945404 hasConceptScore W2590945404C181389837 @default.
- W2590945404 hasConceptScore W2590945404C185592680 @default.
- W2590945404 hasConceptScore W2590945404C191168616 @default.
- W2590945404 hasConceptScore W2590945404C201253974 @default.
- W2590945404 hasConceptScore W2590945404C2777091354 @default.
- W2590945404 hasConceptScore W2590945404C2777239854 @default.
- W2590945404 hasConceptScore W2590945404C2778572730 @default.
- W2590945404 hasConceptScore W2590945404C33923547 @default.
- W2590945404 hasConceptScore W2590945404C43617362 @default.
- W2590945404 hasConceptScore W2590945404C71924100 @default.
- W2590945404 hasConceptScore W2590945404C77281830 @default.
- W2590945404 hasConceptScore W2590945404C98274493 @default.
- W2590945404 hasIssue "1" @default.
- W2590945404 hasLocation W25909454041 @default.
- W2590945404 hasLocation W25909454042 @default.
- W2590945404 hasLocation W25909454043 @default.
- W2590945404 hasLocation W25909454044 @default.
- W2590945404 hasOpenAccess W2590945404 @default.
- W2590945404 hasPrimaryLocation W25909454041 @default.
- W2590945404 hasRelatedWork W2185643343 @default.
- W2590945404 hasRelatedWork W2239518411 @default.
- W2590945404 hasRelatedWork W2246106624 @default.
- W2590945404 hasRelatedWork W2944061097 @default.
- W2590945404 hasRelatedWork W3022393458 @default.
- W2590945404 hasRelatedWork W3079952587 @default.
- W2590945404 hasRelatedWork W3215961562 @default.
- W2590945404 hasRelatedWork W4282914216 @default.
- W2590945404 hasRelatedWork W4320718771 @default.
- W2590945404 hasRelatedWork W2460036269 @default.
- W2590945404 hasVolume "14" @default.
- W2590945404 isParatext "false" @default.
- W2590945404 isRetracted "false" @default.
- W2590945404 magId "2590945404" @default.
- W2590945404 workType "article" @default.